BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

计划入组 22 人 · 首次发布于 2025 年 8 月 24 日

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

计划入组 220 人 · 首次发布于 2025 年 1 月 9 日

Rexon-Eye in Dry Eye

计划入组 40 人 · 首次发布于 2020 年 3 月 25 日

PAPD5 inhibitor (Redona therapeutics)

Rexin G

LION/repRNA-CoV2S

Resonea, Inc.

United States

Retina Global

United States

TENNESSEE RETINA

United States

Chronic GVHD Treatment Evolution: Biomarker-Guided Therapy and Steroid-Free Approaches Show Promise

FDA Approves Verona Pharma's Ohtuvayre (ensifentrine) for COPD Maintenance

Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline for Inherited Retinal Diseases